Natera announced an acquisition of Foresight Diagnostics to incorporate phased‑variant enrichment technology into Signatera and to expand into hematologic MRD testing, aiming to boost ctDNA sensitivity. Separately, Guardant Health struck a partnership with Trial Library to combine liquid‑biopsy diagnostics with AI‑driven trial matching and patient navigation across US oncology networks. The Natera deal bundles assay sensitivity tools with operational scale to pursue MRD and hematology markets; Guardant’s tie‑up targets the persistent gap between biomarker detection and trial enrollment. Both moves underscore a consolidation pattern: diagnostics firms are coupling advanced molecular assays with downstream clinical and trial infrastructure to improve adoption and revenue capture. For readers: phased variants are multiple proximal mutations on the same DNA fragment that increase ctDNA detection sensitivity.